TMCnet News
Research and Markets: The Global Predictive Breast Cancer Gene Testing Market to Grow Significantly, From US$422m in 2011 to US$1 Billion by 2018 at a CAGR of 14%DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/qms24g/medipoint) has announced the addition of the "MediPoint: Predictive Breast Cancer Gene Testing - Global Analysis and Market Forecasts" report to their offering. Myriad Losing Grip on Predictive Breast Cancer Gene Testing Market The US represents the largest predictive breast cancer gene testing market, and Myriad Genetics' intellectual property rights mean that opportunities for new market entrants are restricted to non-BRCA testing, which constitutes only 1% of the region's gene testing market. However, 2015-2018 will mark the expiry of several patents and licenses relating to Myriad Genetics' flagship BRAC Analysis gene test, opening up competition in the US. Myriad Genetics' patents are less enforced abroad, and new opportunities are already present for BRCA tests in Europe. Dr. Thompson states: Myriad Genetics hopes to expand in Europe, but the market consists o many players who are currently offering tests, while infringing Myriad Genetics' patents. The last 12 months have seen DNA Sequencer manufacturers make significant acquisitions of niche genetic testing laboratories, in an apparent move to compete in the clinical genetic testing market, representing a potential threat to Myriad Genetics. China offers the greatest breast cancer gene testing market opportunities, with the large population suffering rising numbers of breast cancer cases as lifestyles change. The country's relatively advanced healthcare industry allows for significant growth in genetic testing processes, whereas Brazil and India hold limited opportunities due to a lack of affordable healthcare. However, a great need arises for low-cost gene testing at a community level in India, based on a breast cancer mutation prevalent in the Indian population. This report provides information on the breast cancer gene testing market, including diagnosis rates, patient segmentation, treatment rates, procedure volumes, average selling prices, and market values over a 10 year period (2009-2018). Companies Mentioned: -23AndMe -Ambry Genetics -ATS GeneTech -BGI-Shenzhen -Bioscientia GmBH -Centogene AG (Centogene Rostock GmBH) -Complete Genomics -Diagnosticos da America SA (DASA) -Grupo Fleury -Illumina -Lab21 Ltd. -Life Technologies -Myriad Genetics -Navigenics (now Life Technologies) -NewGene Ltd. -PreventionGenetics -Roche -Sistemas Genomicos -The Doctors Laboratory Ltd. For more information visit http://www.researchandmarkets.com/research/qms24g/medipoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. |
